Multiple Firms File Securities Class Actions Against Telix in Indiana Federal Court Over Prostate Cancer Program Disclosures

Investors have until January 9, 2026 to seek lead-plaintiff status under the PSLRA.

Overview

Cases were filed on behalf of purchasers of Telix securities between February 21, 2025 and August 28, 2025.
Complaints allege Telix and certain executives overstated progress on prostate cancer therapeutic candidates and the reliability of its supply chain and partners.
Filings point to Telix’s July 22, 2025 disclosure of an SEC subpoena concerning disclosures on its prostate cancer therapeutics, after which ADSs fell more than 13% over two sessions.
Plaintiffs cite Telix’s August 28, 2025 disclosure of an FDA Complete Response Letter for TLX250-CDx referencing CMC deficiencies and Form 483 notices to two third‑party manufacturers, followed by a more than 21% ADS decline over two sessions.
No class has been certified as firms including Robbins Geller, The Schall Law Firm, Bragar Eagel & Squire, Bronstein Gewirtz & Grossman, The Rosen Law Firm, and Holzer & Holzer solicit investors in the Southern District of Indiana case.